- XMeNa patent granted in Australia.
- Water Soluble patent granted in Brazil
- Tax-dox-mix notice of allowance for the patent in Brazil.
Uppsala, Sweden, December 29, 2020 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, secures further valuable IP rights in Australia and Brazil.
XMeNa platform patent granted in Australia – a major market within the Oceania region
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17™, a drug-delivery system currently used with paclitaxel and other cancer drugs. The patent is important for Oasmia as it expands the territories for exclusivity of the key technology XR‑17 used in our lead product Apealea® (paclitaxel micellar), which is being launched in key markets globally.
Francois Martelet, Chief Executive Officer of Oasmia commented “The XMeNa patent is already approved in several major pharmaceutical markets, including the US. With the XMeNa patent now approved in Australia, Oasmia has secured valuable IP protection for the major Oceania market with a significant pharmaceutical market.”
“Water Soluble” patent granted in Brazil
The newly approved “Water soluble” patent is related to a novel nanoparticular formulation of a water soluble pharmaceutically active substances, such as doxorubicin, in combination with Oasmia’s patented technology XR-17. Doxorubicin is used to treat a variety of different forms of cancer such as acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, amongst others.
The patent is also related to the product candidate Doxophos Vet® which Oasmia developed for the treatment of lymphoma, the most common cancer in dogs.
Brazil is among the Top 10 Pharmaceutical Markets Worldwide and Oasmia is now positioned to secure market exclusivity in Brazil under its national patent law.
“Tax-dox-mix” patent receives notice of allowance in Brazil
The tax-dox-mix patent is related to the Oasmia project OAS-19 and focuses on the treatment of various cancers in humans. The patent covers a combination of a wide range of water soluble and water insoluble chemotherapeutic drugs in a single XR-17 containing solution. With an innovative dual chemotherapeutic agent encapsulation and release mechanism, this approach is intended to allow the administration of one single infusion containing two active pharmaceutical ingredients.
For more information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company’s proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.vivesto.com.